Compare Roundhill Magnificent Seven ETF (MAGS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs Viatris Inc — how do they compare? Roundhill Magnificent Seven ETF trades at $67.78, while Viatris Inc trades at $16.24 (market cap $18.69B). The key difference: Viatris Inc pays a 2.95% dividend while Roundhill Magnificent Seven ETF pays none. Which is the better fit depends on your goals.
| MAGS | VTRS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.94 | $17.86 |
52-Week Low | $55.39 | $9.49 |
Market Cap | — | $18.69B |
Enterprise Value | — | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS trades at $67.95, down 1.58% today, with technical indicators showing a bullish moving average trend but overbought RSI levels. The ETF holds equal-weighted exposure to the Magnificent Seven tech stocks, which have underperformed the broader market this year amid shifting investor focus toward semiconductors and AI infrastructure. Recent news highlights concerns over aggressive AI capital spending pressuring dividends and buybacks.
The outlook remains cautious as AI profit realization lags expectations, though hyperscaler valuations are compressed. Key risks include concentration in tech, high expectations, and macroeconomic sensitivity. Analyst sentiment is mixed, with some seeing long-term AI potential but near-term headwinds from earnings pressure and market rotation.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
